McKesson Corporation (NYSE:MCK) said on Monday it will acquire privately held Precision Medicine Group in a deal valued at about $2.25 billion, the latest move in what the company described as a years-long effort to strengthen its higher-growth businesses. Reuters reported the announcement, which centers on bolstering McKesson's oncology and precision medicine capabilities at a time when drug distributors are looking to move up the healthcare value chain.
Precision Medicine Group is a privately held company focused on oncology and personalized treatment services, an area that has drawn sustained investor interest as cancer care shifts toward genomic profiling, targeted therapies, and data-driven clinical decision-making. McKesson did not immediately disclose additional financial terms beyond the headline valuation, and the company said the transaction is expected to close subject to customary regulatory approvals and closing conditions.
ALSO READ | Food Bank for NYC Urges Congress to Halt SNAP Cost Shift and Fully Fund Emergency Aid
The deal comes as McKesson has been reshaping its portfolio by exiting non-core assets and streamlining operations, a strategy that has redirected capital toward segments such as oncology, biopharma services, and specialty distribution. Company executives have framed oncology and related precision-medicine adjacencies as central to the distributor's long-term growth plan, citing demand from biopharmaceutical manufacturers and providers for more sophisticated commercialization and evidence-generation support.
For the broader pharmaceutical services sector, the transaction underscores continued consolidation as distributors and contract service providers compete to capture a larger share of the value created by complex oncology therapies. Analysts tracking the sector have pointed to rising contract development and commercialization activity tied to personalized medicine as a key growth lever for established players willing to make sizable bets. McKesson's $2.25 billion purchase price signals its conviction that precision oncology will remain a durable, high-margin expansion area even as the broader generics and traditional wholesale drug distribution businesses face pricing pressure.
The acquisition adds to a string of investments McKesson has made in oncology-focused services, reflecting the company's effort to position closer to manufacturers of cutting-edge cancer treatments and the providers who administer them. Precision Medicine Group's existing footprint in oncology diagnostics support and clinical services is expected to integrate with McKesson's broader US Oncology Network and specialty distribution operations once the transaction closes.
